AbCellera Biologics (ABCL) Net Cash Flow (2020 - 2026)

AbCellera Biologics has reported Net Cash Flow for 7 years, with the latest figure at -$51.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 2286.81% year-over-year to -$51.4 million; the trailing twelve-month figure through Mar 2026 stood at -$83.2 million (down 325.3% YoY), and the FY2025 full-year result was -$29.5 million, down 214.99% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$51.4 million, down from $44.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $247.0 million in Q2 2022, with the low at -$408.8 million in Q3 2022.
• Historically, Net Cash Flow has averaged -$22.8 million across 5 years, with a median of -$8.7 million in 2025.
• Annual changes were most pronounced in 2024 — Net Cash Flow jumped 276.17% — and 2026, when it slumped 2286.81%.
• AbCellera Biologics' Net Cash Flow stood at $14.2 million in 2022, then sank by 382.92% to -$40.2 million in 2023, then surged by 179.28% to $31.8 million in 2024, then jumped by 39.77% to $44.5 million in 2025, then tumbled by 215.51% to -$51.4 million in 2026.
• The last three Net Cash Flow figures came in at -$51.4 million (Q1 2026), $44.5 million (Q4 2025), and -$8.7 million (Q3 2025), per Business Quant data.